Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

This study is testing the combination of two cancer drugs — pembrolizumab (immunotherapy) and lenvatinib (targeted therapy) — in women with cervical cancer that has come back or spread and has already been treated with prior chemotherapy. **You may be eligible if...** - You are a woman, 18 or older - You have been diagnosed with recurrent or metastatic cervical cancer (squamous, adenocarcinoma, or adenosquamous) - You have received up to 2 prior lines of chemotherapy for advanced or recurrent disease - You may have received prior immunotherapy or bevacizumab **You may NOT be eligible if...** - You have uncontrolled or serious health conditions such as severe heart disease, uncontrolled high blood pressure, or active significant bleeding - You are pregnant or breastfeeding - You have active, untreated brain metastases Talk to your doctor to see if this trial is right for you.